December 19, 2023 Acad, Gov/Utilities Lab Top-10 Molecular Spectroscopy

Bruker Announces First 1.2 GHz NMR Installation in the United States at The Ohio State University – Funded by the U.S. National Science Foundation

Novel GHz-class NMR systems are enabling unprecedented life science and materials research in functional structural biology, drug discovery, metabolomics and cleantech research. COLUMBUS, Ohio–(BUSINESS WIRE)– Bruker Corporation, the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions for life and materials research, today announced the successful installation of a 1.2 Gigahertz (GHz) NMR system at... Read more

December 19, 2023 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure Interim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction 17 million people in the U.S. have confirmed... Read more

December 15, 2023 Environ, Ag./Food & Bev PR/Corporate

Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in innovation management, access to healthcare, greenhouse gas emissions, water management, resource efficiency and circularity, labour practice indicators and human rights This marks the 15th consecutive year that Roche has maintained its leading ranking Basel, 15... Read more

December 11, 2023 PAI Top-10 Product Launch

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 – Roche (SIX: RO, ROG;... Read more

December 9, 2023 PAI Top-10 Product Launch

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1 At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of... Read more

December 8, 2023 PAI Top-10

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2 Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2 These data will be presented as an oral presentation at the 2023 San Antonio... Read more

December 8, 2023 Uncategorized

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1 The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium... Read more